10-K/A: enVVeno Medical Corporation Files Form 10-K/A, Clarifies VenoValve FDA Decision Timeline

enVVeno Medical Corporation amends its Form 10-K to clarify that an FDA decision on its lead product, VenoValve, is expected in the second half of 2025.

Summary

• enVVeno Medical Corporation, a late clinical-stage medical device company, filed an amendment to its Form 10-K to clarify the expected timeline for an FDA decision on its VenoValve product.
• The company anticipates a decision from the U.S. Food and Drug Administration regarding the VenoValve in the second half of 2025.
• enVVeno is focused on developing bioprosthetic solutions for venous disease, with two main products: the VenoValve (surgical) and enVVe (non-surgical).
• The VenoValve is currently in a U.S. pivotal study, while enVVe is undergoing pre-clinical testing.
• The company reported net losses of $21.8 million for 2024, compared to $23.5 million in 2023.
• Research and development expenses decreased by $1.4 million to $12.2 million in 2024.
• Selling, general, and administrative expenses decreased slightly by $0.1 million to $11.6 million in 2024.
• The company's cash balance as of December 31, 2024, was $1.8 million, with an additional $41.4 million in investments, totaling $43.2 million.
• enVVeno anticipates its cash burn rate will increase from $4-5 million per quarter to $5-6 million per quarter in 2025.
• The company believes it has sufficient cash to fund operations through mid-2026 but will need to raise additional capital in the future.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the company is still operating at a loss, it is moving towards potential FDA approval of its lead product. The need for future capital raises is a concern, but is typical for companies at this stage.

Positives

• The company anticipates an FDA decision on its VenoValve product in the second half of 2025.
• Research and development expenses decreased by $1.4 million to $12.2 million in 2024.
• Selling, general, and administrative expenses decreased slightly by $0.1 million to $11.6 million in 2024.

Negatives

• The company reported a net loss of $21.8 million for the year ended December 31, 2024.
• The company anticipates its cash burn rate will increase to $5-6 million per quarter in 2025.
• enVVeno believes it has sufficient cash to fund operations through mid-2026 but will need to raise additional capital in the future.

Risks

• The company's future success depends on FDA approval of its product candidates, which is not guaranteed.
• The company has a history of operating losses and may not achieve profitability.
• The company will need to raise additional capital in the future, and there is no guarantee that it will be able to do so on acceptable terms.
• The company faces significant competition in the medical device industry.
• Product liability lawsuits could cause the company to incur substantial liabilities.

Future Outlook

The company expects to receive FDA approval for its VenoValve in the second half of 2025 and anticipates an increased cash burn rate in 2025. The company will need to raise additional capital in the future.

Management Comments

• With the filing of our final PMA module completed in December 2024, we hope to receive FDA approval during the second half of 2025, and we have commenced limited activity toward commercial launch in anticipation of that approval.
• We anticipate that our cash burn rate will increase from current levels of approximately $4 million to $5 million per quarter to $5 million to $6 million per quarter in 2025.
• Based upon our cash and working capital as of December 31, 2024, we have sufficient capital resources to meet our obligations as they become due within at least one year after the date of this Annual Report and sustain operations.

Industry Context

enVVeno Medical is operating in the venous disease treatment market, which is characterized by a high prevalence of chronic venous disease and a lack of effective treatments for deep venous CVI caused by incompetent valves. The company's VenoValve and enVVe products aim to address this unmet need.

Comparison to Industry Standards

• The document does not provide enough information to make a detailed comparison to industry standards.
• To assess enVVeno's performance against industry benchmarks, we would need data on comparable companies, projects, and results, such as clinical trial success rates, regulatory approval timelines, and commercialization metrics.
• Without specific comparables, it's difficult to determine if enVVeno's progress is ahead, behind, or in line with industry norms.

Related Party Transactions

• Perceptive Life Sciences Master Fund, Ltd., a holder of greater than 5% of our Common Stock, participated as an investor in a financing with the Company pursuant to a purchase agreement that was executed on October 6, 2023.

Stakeholder Impact

• Shareholders: The company's future performance and stock price are dependent on FDA approval and successful commercialization of its products.
• Employees: The company's ability to continue operations and develop its products depends on its financial resources.
• Patients: Successful development and approval of the VenoValve and enVVe could provide new treatment options for venous disease.

Next Steps

• The company expects to receive an FDA decision on the VenoValve in the second half of 2025.
• The company expects to file for IDE approval for the enVVe pivotal study in mid-2025.
• The company will need to raise additional capital in the future.

Key Dates